Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263 · View on ClinicalTrials.gov ↗
Study Summary
Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may become swollen and red over time. If they fill with pus, these lumps are called abscesses; these can also burst. Over time, the area can get scars and tunnels on or under the skin. Recent studies suggest that the condition may start when hair follicles become damaged and blocked. This impacts the skin and may activate the body's germ-fighting (immune) system. This allows bacteria to grow on the skin which worsens the condition and can cause abscesses. The main aims of this study are to learn how safe zasocitinib is, how well it works and how well adults with HS tolerate it compared with a placebo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 4 months (16 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. After the first 4 months, all participants (also those who initially received placebo) will then receive zasocitinib for up to 8 months (36 weeks). During the study, participants will visit their study clinic 12 times.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Zasocitinib (Dose A)
Study Locations (20)
Victoria
- Skin Health Institute Inc. — Carlton
- Sinclair Dermatology — Melbourne
- Alfred Hospital — Melbourne
Florida
- Direct Helpers Research Center — Hialeah
- Advanced Clinical Research Institute — Tampa
Michigan
- Wayne State University — Detroit
- Hamzavi Dermatology — Fort Gratiot
New York
- Northwell Health Physician Partners — Lake Success
- Mount Sinai Doctors — New York
Texas
- Arlington Research Center, Inc. — Arlington
- Texas Dermatology Research Center — Dallas
New South Wales
- Skin & Cancer Foundation - The Skin Hospital — Darlinghurst
- Westmead Hospital — Westmead
Arizona
- Mayo Clinic — Scottsdale
Arkansas
- Johnson Dermatology — Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-01-26 |
| Est. Completion | 2028-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07244263
The ClinicalTrials.gov registry entry for NCT07244263 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 387 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07244263 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Victoria, Florida, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07244263 about?
NCT07244263 is a clinical study titled "A Study of Zasocitinib in Adults With Hidradenitis Suppurativa". Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may become swollen and red over time. If they fill with pus, these lumps are called abscesses; these can al...
What is the current status of trial NCT07244263?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-01-26. Estimated completion is 2028-02-22.
What conditions does trial NCT07244263 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07244263?
The interventions under investigation include: Placebo (OTHER), Zasocitinib (Dose A) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07244263?
This trial is sponsored by Takeda, which has 387 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07244263 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.